DDAVP Articles
Barr's profits up 24% to $76M
15 May 2006
Teva's generic desmopressin cleared in USA
6 February 2006
FDA Approval News In Brief
2 April 1998
R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr
4 November 1996
R-PR Posts Profits Climb But Flat Turnover In First Half
5 August 1996
Rhone-Poulenc Rorer Beats 1st-Qtr Forecasts
6 May 1996
R-PR To launch Oral Diabetes Insipidus Drug
19 February 1996
ALKERMES UNVEILS ORALEASE DATA
4 July 1994
DESMOPRESSIN NASAL SPRAY
9 May 1994
RHONE-POULENC RORER '93 RESULTS BELOW EXPECTATIONS
7 February 1994
RHONE-POULENC: A TRANSFORMATION
16 August 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
RHONE-POULENC RORER SALES $4 BILLION IN 1992
8 February 1993
RHONE-POULENC RORER NET INCOME UP 13.4%
2 November 1992
Showing 1-16 of 16 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
